FDA Regulation of Consumer Infant Monitors: General Wellness vs. Medical Device Claims

FDA regulation of consumer infant monitors: where general wellness ends and device claims begin

Consumer infant monitors that report a baby's pulse rate, oxygen saturation (SpO2) or breathing sit on one of the most closely watched lines in FDA's digital health policy. FDA's position has been consistent. A product that measures an infant's SpO2 and pulse rate and alerts caregivers when readings leave preset ranges is a medical device, not a general wellness product. Since November 2023, these products have a dedicated Class II pathway for over-the-counter (OTC) use.

Key takeaways

• Enforcement first, pathway second. In an October 5, 2021 warning letter, FDA told Owlet Baby Care that its Smart Sock products were devices marketed without clearance, approval or authorization ⁴⁷¹⁵⁸. FDA said it had told Owlet since 2016 that the Smart Sock did not fall under the General Wellness compliance policy ¹⁵⁶.
• A dedicated OTC classification now exists. FDA granted the Owlet Dream Sock De Novo (DEN220091) on November 8, 2023. The grant created product code QYU, "infant pulse rate and oxygen saturation monitor for over-the-counter use," under 21 CFR 870.2705 (Class II, special controls) ^89285326327.
• Only one follow-on OTC clearance so far. The Masimo Stork (K234021, May 3, 2024) is the only 510(k) under QYU, and it cites the Dream Sock as its predicate ³²⁴³⁹⁶. Prescription-only home infant oximeters are a separate route: BabySat 3 (K222597) and an earlier Masimo Stork clearance (K223721) ³¹⁷⁴⁷¹.
• SIDS claims are off the table. In announcing the Dream Sock, FDA said the device's safety and effectiveness for detecting or preventing SIDS/SUID "has not been established" ⁸².
• The general wellness line is drawn at clinical purpose and alerting. FDA's January 6, 2026 General Wellness: Policy for Low Risk Devices guidance (which supersedes the September 27, 2019 version) excludes products that report physiologic values for "screening, diagnosis, monitoring, alerting, or management of a disease or condition" ²¹⁸³⁷⁹.

The device classification landscape

Several existing classifications are relevant to infant monitoring. Which one applies depends on the measured parameter, the intended population, and whether the product is labeled for prescription or OTC use.

Three regulatory points stand out:

• Oximetry. Under 21 CFR 870.2700, an oximeter is a device that transmits radiation at known wavelengths through blood to measure blood oxygen saturation. It is Class II ⁴²⁴³. FDA recognizes wellness and sporting/aviation oximeters (PGJ, OCH) as categories under enforcement discretion. Wearable continuous monitoring for infants is not one of those categories ²³⁴²³⁶.
• Breathing and apnea. Under 21 CFR 868.2377, an apnea monitor is "a complete system intended to alarm primarily upon the cessation of breathing timed from the last detected breath." The definition also covers "indirect methods of apnea detection such as monitoring of heart rate and other physiological parameters linked to the presence or absence of adequate respiration." It is Class II, and its special control is FDA's apnea monitor special controls guidance ⁴⁵⁴⁶. A consumer product that alarms on absent breathing therefore falls within an existing device type, even if it uses indirect sensing.
• OTC infant SpO2/PR monitoring. Before 2023, no classification covered an OTC wearable that reports infant SpO2 and pulse rate and alerts lay caregivers. The De Novo filled that gap (see below).

Enforcement: the 2021 Owlet Smart Sock warning letter

FDA's October 5, 2021 warning letter to Owlet Baby Care was titled "Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device." It covered Smart Sock versions 1 to 3, the Smart Sock Plus and co-packaged products ⁴⁷¹⁵³.

The claims FDA cited. The letter quoted retail and company marketing, including:

• "Track the most important indicators of your baby's health–like oxygen level, heart rate, and total hours slept" ²⁹⁸
• "If your baby's readings leave preset 'safe' zones, the Smart Sock will immediately notify you that your baby needs your attention" ²⁹⁸
• "We look at the best indicators of your baby's overall well-being and will proactively notify you if your baby may need you" ²⁹⁹
• "Rest easy knowing you'll receive proactive notifications via lights and sounds if your baby's oxygen level or heart rate leave preset zones" ³⁰⁰
• "Tells you when Baby needs you" ³⁰¹

FDA's device rationale. FDA said products that measure blood oxygen saturation and pulse rate are devices under FD&C Act section 201(h) when they are intended to identify desaturation and bradycardia and to alarm when measurements fall outside preset values ¹⁵⁴¹⁵⁵. FDA also stated that the Smart Sock "does not fall under the compliance policy for low-risk products that promote a healthy lifestyle (General Wellness guidance)" ¹⁵⁶.

Violations and requested actions. FDA charged adulteration under section 501(f)(1)(B) because the devices, as marketed, had neither an approved PMA nor an approved IDE ¹⁵⁸¹⁵⁹. FDA asked Owlet to stop activities such as commercial distribution for those uses and to respond within 15 business days ³⁰²³⁰³.

The takeaway for regulatory teams: FDA did not treat the sleep-tracking element ("total hours slept") as saving the product. The threshold-based notifications on physiologic parameters, framed around infant health, determined device status.

Creating the OTC pathway: Dream Sock De Novo (DEN220091)

FDA granted the Dream Sock De Novo on November 8, 2023. It classified the device as Class II, product code QYU, under 21 CFR 870.2705 ²⁸⁵³⁴.

Identification. 21 CFR 870.2705(a) reads: "An infant pulse rate and oxygen saturation monitor for over-the-counter use is a device that uses photoplethysmography to measure pulse rate and oxygen saturation in infants. The device may contain alarms that alert the caregiver when vital sign(s) go outside preset threshold(s)" ³²⁶.

Special controls (21 CFR 870.2705(b)).

1. Clinical performance testing under anticipated use conditions. This must evaluate confounders such as skin pigmentation, show output consistency across the intended population, and capture all adverse events, including skin irritation ³²⁸.
2. Software verification, validation and hazard analysis, including algorithm specifications and acceptance criteria for incoming sensor-data quality ³²⁹.
3. Non-clinical testing showing detection of adequate photoplethysmography signal quality, plus validation of any alarms ³³⁰.
4. Biocompatibility of skin-contacting components ³³¹.
5. Electrical safety and electromagnetic compatibility ³³².
6. Human factors testing showing a caregiver can use the device correctly from the labeling alone, interpret its outputs, and understand the next steps ³³³.
7. Labeling that identifies the intended population, populations that should not use the device, monitoring conditions, how to interpret outputs and act on them, and situations where performance may not be achieved ³³⁴.

Risks FDA identified. These included:

• missed pulse rate or SpO2 detection from poor signal quality
• misinterpretation of, or over-reliance on, outputs that delays care
• adverse tissue reactions
• false positives that lead to unnecessary procedures
• false negatives that miss pulse rate or low-SpO2 events ²⁸⁸²⁸⁹

Evidence base.

• Pulse-rate accuracy met an ARMS ≤3 bpm criterion, and alarm testing passed ²⁹⁰.
• SpO2 accuracy came from an 18-adult breathe-down study covering 70 to 100% SpO2. SpO2 met RMS <3% and pulse rate met RMS <5 bpm under simulated motion and non-motion conditions. Adults were used because inducing low SpO2 in infants was considered unethical ²⁹¹.
• In human factors validation, all 20 lay caregivers correctly handled the critical notification tasks ²⁹².
• A 43-participant skin study recorded three mild reactions in two participants ²⁹³.

Labeled limitations. The indications are limited to infants 1 to 18 months old weighing 6 to 30 lb, for OTC home use only ³⁵. Notifications:

• supplement caregivers' decisions to seek medical guidance
• are not expected for every event
• occur only when sufficient data are available
• do not replace traditional monitoring, diagnosis or treatment ²⁹⁴

The device is not intended for infants previously diagnosed with cardiovascular or respiratory conditions ³⁵. FDA's public announcement added that the device's safety and effectiveness for detecting or preventing SIDS/SUID "has not been established" ⁸².

FDA concluded that the probable benefits outweigh the probable risks when general and special controls are applied ²⁹⁵²⁹⁶.

Follow-on clearances and the prescription alternative

Masimo Stork (K234021). The OTC Stork 510(k) names the Dream Sock as its predicate and the earlier prescription Stork (K223721) as a reference device ³⁹⁶. Differences from the predicate include:

• a wider age range (0 to 18 months vs. 1 to 18 months)
• added skin-temperature measurement ³⁹⁹
• different SpO2 accuracy specifications ⁴⁰⁰

The clinical evidence included:

• a 30-subject desaturation study (reported ARMS 1.24)
• a 42-infant form, fit and function study across skin pigmentations
• an overnight home-use study in 19 infants and neonates ^408409410411

Like the Dream Sock, its indications say it may supplement a caregiver's decision to seek guidance. They also exclude infants previously diagnosed with cardiovascular or respiratory conditions ³⁹⁷³⁹⁸.

Prescription home oximetry. BabySat 3 shows that a sponsor can avoid the OTC De Novo framework by labeling the product for prescription use under the conventional oximeter classification. BabySat 3 was cleared as a prescription pulse oximeter for home use. Its predicate was the Guardian Angel Rx GA 1001 (K182882), and its testing followed FDA oximeter guidance and ISO 80601-2-61 ^317319320. The prescription Masimo Stork used a similar approach, with a home-use infant monitoring indication and the Guardian Angel Rx GA2000 (K203208) as predicate ⁴⁷²⁴⁷⁴.

Where FDA draws the general wellness line

The two-factor test

Under the January 6, 2026 General Wellness: Policy for Low Risk Devices guidance, a product qualifies only if it meets two conditions:

1. it is intended only for general wellness use, and
2. it presents low risk ²¹⁸²¹⁹.

Wellness claims. These fall into two groups:

• Claims about general health or healthy activity that do not reference disease. Examples include sleep management, tracking sleep trends, and monitoring heart rate during recreation ²²⁰.
• Healthy-lifestyle claims that the product "may help reduce the risk of" or "may help living well with" certain chronic conditions, where the link between lifestyle and health is well understood ²²¹²²⁴.

Low risk. A product is not low risk if it is invasive, implanted, or uses a technology that may pose safety risks without specific regulatory controls. FDA also asks whether CDRH actively regulates the same product type ²³⁰²³¹. A "yes" to any of the risk questions takes a product outside the guidance ³⁷⁴.

Non-invasive physiologic sensing

The 2026 guidance says FDA "may consider" non-invasive products that estimate parameters such as oxygen saturation, blood pressure, blood glucose and heart-rate variability to be general wellness products. This applies only when the outputs are intended solely for wellness uses ³⁷⁵. The conditions are:

• no diagnostic, preventive or treatment intent related to disease
• no substitution for an FDA-authorized device
• no prompting or guiding of specific clinical action
• validation of any values that mimic clinically used values ³⁷⁵

Qualifying products may display "values, ranges, trends, baselines, or longitudinal summaries" in wellness contexts such as sleep, activity, stress or recovery ³⁷⁷. FDA's example of a product that monitors pulse rate and/or oxygen saturation during exercise and hiking meets both factors, because the claim "relates only to exercise and hiking and does not refer to a disease or medical condition" ²²⁸.

Notifications are allowed only in a narrow form. A product may tell the user that evaluation by a healthcare professional "may be helpful" when an output falls outside a wellness range. That message must not:

• name a disease
• call the output abnormal or diagnostic
• supply clinical thresholds or treatment recommendations
• provide ongoing disease-management alerts ³⁷⁸

What takes a product outside the policy

FDA excludes products intended to report physiologic values for "medical or clinical purposes," including "screening, diagnosis, monitoring, alerting, or management of a disease or condition" ³⁷⁹. The guidance also excludes products whose labeling, advertising, interface or functionality does any of the following:

• refers to specific diseases or diagnostic thresholds
• recommends or requires specific clinical action through alerts, alarms or prompts
• gives treatment guidance
• claims clinical equivalence, clinical accuracy or substitution for an authorized device ³⁸⁰

Claims about a wellness wearable's functions that imply medical or clinical use also remove it from the policy ³⁸¹.

Applying the line to infant monitors

FDA's recorded actions and the guidance text together point to a practical boundary:

The adult wellness examples in the guidance do not carry over to infant SpO2 monitoring in any straightforward way. In infant monitoring, the core consumer value proposition is reassurance that the baby is physiologically safe, delivered through threshold alerts. FDA's own language describes that as "monitoring" and "alerting" ³⁷⁹. The QYU identification also expressly anticipates such alarms ³²⁶. The 2026 guidance text reviewed here does not set out a separate infant-specific rule ¹⁹⁹. In practice, FDA's enforcement record and the existence of a dedicated OTC classification define the boundary for this product class.

The pulse oximetry guidance reinforces the split

FDA's January 7, 2025 draft guidance Pulse Oximeters for Medical Purposes lists both OLK and QYU as in-scope medical-purpose devices. It excludes general wellness oximeters under codes OCH and PGJ, which FDA does not review before they reach the market ^182183188. For devices intended for children younger than 12, the draft recommends pediatric performance validation. For neonatal use, it recommends additional neonatal samples ¹⁶⁴¹⁹². It defines infants as 1 month to under 2 years for OTC pediatric labeling ¹⁷⁰. In its accompanying announcement, FDA said many OTC oximeters fall into the general wellness or sporting/aviation group and have not been evaluated by FDA for clinical decision-making ⁸⁴⁸⁵⁸⁶. The 2013 final 510(k) guidance for pulse oximeters remains in effect until the draft is finalized ¹⁸⁵¹⁸⁹.

Adjacent enforcement: infant sleep products

FDA's June 15, 2026 warning letter to Happiest Baby, Inc. concerns supine-positioning sleep products, not vital-sign monitors ⁵⁰³³⁶. It still shows how the agency handles infant products positioned near the wellness line. FDA rejected the firm's position that a hospital version of the SNOO was only a soothing tool. FDA found that its claims and design showed an intended use of facilitating supine sleep, which made it a device. FDA also said the product was not a general wellness use and not low risk under that policy ^341342343. FDA further alleged that new sleep-sack sizes and hospital marketing went beyond the scope of the original De Novo (DEN210039), which covered home use ^344345346. For infant monitor sponsors, the parallel is direct: changing the indicated population, care setting or accessories after authorization can trigger a new premarket submission.

Practical implications for regulatory teams

• Claims drive classification. Any combination of infant SpO2 or pulse rate with threshold notifications, "safe zone" language or "needs you" messaging has been treated as device marketing ^298300154. Removing the notifications while keeping infant-health framing does not clearly qualify a product for the wellness policy, because "monitoring" of a condition is excluded on its own ³⁷⁹.
• Choose the pathway deliberately. OTC products with infant SpO2/pulse-rate alerts now have a predicate route to 510(k) under QYU ⁹⁴³⁹⁶. Prescription home oximeters can still use the oximeter classification with a prescription-labeled predicate ³¹⁷³¹⁹.
• Plan evidence to the special controls. Sponsors should expect to provide:
  • adult desaturation data supplemented by infant form, fit and function data across skin pigmentation
  • signal-quality and alarm validation
  • lay-caregiver human factors validation
  • skin-reaction data ^{291292293328333}
• Labeling must manage over-reliance. Authorized labeling says the device supplements caregiver decisions and does not replace clinical monitoring. It excludes infants with diagnosed cardiovascular or respiratory conditions and makes no SIDS claim ^3582294.
• Breathing-only monitors need their own analysis. Products that alarm on absent breathing map to the apnea monitor regulation, including where detection is indirect ⁴⁵⁹².

Questions worth pursuing further include how FDA's 2026 wellness revisions compare with the 2019 text on non-invasive sensing, and the content of the apnea monitor special controls guidance.